Can I Take Ashwagandha with Zetia (Ezetimibe)?

How Ezetimibe Works and Why Interactions Matter

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter on the brush border of small intestinal enterocytes, reducing dietary and biliary cholesterol absorption by approximately 54% [1]. Unlike statins, it does not inhibit HMG-CoA reductase. It also does not rely heavily on cytochrome P450 enzymes for clearance.

Ezetimibe's Metabolic Pathway

After oral absorption, ezetimibe undergoes rapid glucuronidation in the intestinal wall and liver, forming ezetimibe-glucuronide. This conjugate is pharmacologically active and recirculates via enterohepatic recycling [2]. The primary enzymes responsible are UGT1A1 and UGT1A3. Because CYP450 involvement is minimal, ezetimibe has a narrow interaction profile compared to statins.

What the FDA Label Lists

The ezetimibe prescribing information flags interactions with cyclosporine (which raises ezetimibe exposure 12-fold), fibrates (increased gallstone risk), and bile acid sequestrants like cholestyramine (which reduce ezetimibe bioavailability by 55%) [1]. Ashwagandha does not appear on the label, in the Natural Medicines Comprehensive Database severe-interaction category, or in FDA MedWatch safety reports for ezetimibe.

Why This Matters for Supplements

The absence of a listed interaction does not guarantee safety. Supplements are rarely tested in formal drug-interaction trials. The relevant question is whether ashwagandha's known pharmacology overlaps with ezetimibe's metabolic or therapeutic pathways in a way that could change drug levels or clinical outcomes.

Ashwagandha's Pharmacology: What Reaches the Liver

Ashwagandha (Withania somnifera) root extract contains withanolides, primarily withaferin A and withanolide D. These compounds are absorbed orally and undergo hepatic metabolism [3].

In Vitro CYP450 Data

A 2020 in vitro study published in Drug Metabolism and Disposition found that withaferin A inhibits CYP2D6 and CYP3A4 at concentrations above 10 µM [4]. Whether standard oral doses (300 to 600 mg of root extract daily) produce these concentrations in human hepatocytes remains unconfirmed. No published human pharmacokinetic interaction study has tested ashwagandha against ezetimibe or any UGT-metabolized drug.

The Glucuronidation Question

Ezetimibe's reliance on UGT1A1 and UGT1A3 rather than CYP3A4 or CYP2D6 means that even if ashwagandha inhibits those CYP enzymes at clinical doses, the effect on ezetimibe clearance would be negligible. No published data show that withanolides inhibit UGT1A1 or UGT1A3 [2]. This is the strongest pharmacokinetic argument for compatibility.

Bottom Line on Drug Levels

Based on current evidence, ashwagandha is unlikely to raise or lower ezetimibe blood concentrations. The metabolic pathways do not overlap in a clinically meaningful way. The real considerations are pharmacodynamic, not pharmacokinetic.

Pharmacodynamic Considerations: Thyroid, Cortisol, and Lipids

Even without a direct drug-level interaction, ashwagandha can shift biomarkers that your prescriber monitors alongside ezetimibe therapy.

Thyroid Hormone Elevation

A 2018 randomized, double-blind, placebo-controlled trial (N=50) in subclinical hypothyroid patients found that ashwagandha root extract at 600 mg daily for 8 weeks significantly increased serum T4 (from 7.3 to 8.7 µg/dL) and T3 (from 2.3 to 3.2 pg/mL) compared to placebo [5]. Thyroid hormones directly regulate hepatic LDL receptor expression. Hypothyroidism raises LDL-C. Conversely, a shift toward higher thyroid function can lower LDL-C independently of ezetimibe [6].

This creates a monitoring consideration, not a danger. If your lipid panel improves after starting ashwagandha, part of that change may reflect thyroid modulation rather than the cholesterol drug working better. Your prescriber needs to know both interventions are in play to interpret labs accurately.

Cortisol Reduction

A 60-day RCT (N=64) by Chandrasekhar et al. Found that ashwagandha 600 mg daily reduced serum cortisol by 27.9% versus placebo (P<0.001) [7]. Chronic cortisol elevation promotes visceral adiposity, insulin resistance, and dyslipidemia. Lowering cortisol may therefore produce small, favorable lipid shifts.

The Endocrine Society's 2023 clinical practice guideline on dyslipidemia notes that "secondary causes of hyperlipidemia, including thyroid dysfunction and cortisol excess, should be excluded or treated before attributing lipid abnormalities to primary causes" [8]. If ashwagandha modifies both thyroid and cortisol axes, it becomes a confounder in lipid management that warrants documentation in the medical record.

Ashwagandha's Direct Lipid Effects

Some clinical data suggest ashwagandha itself has mild lipid-lowering properties. A 2024 systematic review and meta-analysis of 12 RCTs (N=897) found statistically significant reductions in total cholesterol (weighted mean difference: -10.3 mg/dL, 95% CI: -15.1 to -5.5) and LDL-C (-7.8 mg/dL) with ashwagandha supplementation [9]. These effects are modest compared to ezetimibe's typical 18 to 20% LDL-C reduction, but they may contribute additively.

What About Testosterone?

Ashwagandha is widely marketed for testosterone support. A 2019 RCT (N=57) of overweight men aged 40 to 70 found that ashwagandha extract (600 mg/day for 8 weeks) increased testosterone by approximately 15% versus placebo [10]. Testosterone itself has complex effects on lipid profiles, and exogenous testosterone replacement can lower HDL-C.

Clinical Relevance for Ezetimibe Users

The testosterone increase seen with ashwagandha supplementation is modest (typically 50 to 100 ng/dL in hypogonadal-range men) and unlikely to produce the HDL-suppressing effect associated with supraphysiologic testosterone doses. For most ezetimibe users, this is a non-issue. If you are on concurrent testosterone replacement therapy and ezetimibe, adding ashwagandha warrants a conversation with your prescriber about monitoring frequency.

Dose and Timing Guidance

No evidence-based dose-separation window exists for ashwagandha and ezetimibe. Ezetimibe can be taken at any time of day with or without food, and its enterohepatic recycling creates a long effective half-life of approximately 22 hours [1].

Practical Recommendations

Take ezetimibe at whatever time you already take it. Ashwagandha can be taken with meals to reduce gastrointestinal discomfort. There is no pharmacokinetic reason to separate the two by a specific number of hours.

If you take a bile acid sequestrant like cholestyramine (which some patients use alongside ezetimibe), separate the ashwagandha from the sequestrant by at least 2 hours. Bile acid resins bind many compounds nonspecifically and could reduce ashwagandha absorption.

Dose Ranges in Published Trials

Most positive ashwagandha trials used KSM-66 or Sensoril standardized extracts at 300 to 600 mg daily [7][10]. Doses above 600 mg have not shown proportionally greater benefits and may increase the risk of GI side effects and hepatotoxicity, which brings up the next consideration.

Liver Safety: A Shared Concern

Both ezetimibe and ashwagandha have rare associations with hepatotoxicity.

Ezetimibe and the Liver

Post-marketing reports include cases of elevated transaminases and, rarely, hepatitis associated with ezetimibe [1]. The IMPROVE-IT trial (N=18,144), which tested ezetimibe plus simvastatin versus simvastatin alone over a median of 6 years, did not find a statistically significant increase in hepatic adverse events with ezetimibe [11]. The rate of persistent ALT/AST elevation greater than 3 times the upper limit of normal was 2.5% in the combination group versus 2.3% with simvastatin alone.

Ashwagandha and the Liver

The American College of Gastroenterology's Clinical Guideline on Drug-Induced Liver Injury (2023) identifies ashwagandha as an emerging cause of herbal hepatotoxicity [12]. Case reports describe cholestatic or mixed-pattern liver injury within 2 to 12 weeks of starting ashwagandha, typically resolving after discontinuation. The Iceland DILI registry documented ashwagandha as the second most common herbal cause of liver injury after green tea extract [13].

Combined Monitoring Strategy

If you take both, a reasonable approach is to check a comprehensive metabolic panel including ALT and AST at baseline, then again at 6 to 8 weeks after starting ashwagandha. Dr. Victor Navarro, hepatologist and principal investigator of the Drug-Induced Liver Injury Network (DILIN), has stated: "Patients using herbal supplements alongside prescription medications should have liver enzymes checked within the first two months, especially when both agents have hepatotoxic potential" [12].

Stop ashwagandha and contact your prescriber if ALT or AST exceeds 3 times the upper limit of normal or if you develop jaundice, dark urine, or right upper quadrant pain.

Who Should Avoid This Combination

Certain populations face higher risk.

Autoimmune Thyroid Disease

Ashwagandha's thyroid-stimulating effect makes it inappropriate for patients with Graves' disease or uncontrolled hyperthyroidism. If you take ezetimibe because statin intolerance limits your lipid-lowering options and you also have autoimmune thyroid disease, avoid ashwagandha.

Active Liver Disease

Patients with baseline transaminase elevations, non-alcoholic steatohepatitis (NASH), or any chronic liver condition should not add ashwagandha without hepatology clearance. Ezetimibe is generally safe in compensated liver disease, but stacking a second agent with hepatotoxic case reports is not justified by ashwagandha's modest benefits.

Pregnancy and Lactation

Ashwagandha is classified as possibly unsafe during pregnancy based on animal data showing abortifacient effects at high doses [3]. Ezetimibe is pregnancy category C (now described by narrative risk in the FDA's updated labeling format). Neither should be used in pregnancy without explicit guidance.

Immunosuppressed Patients

Ashwagandha may stimulate immune activity. Patients on cyclosporine (which already interacts with ezetimibe) should avoid ashwagandha entirely due to the risk of altering immunosuppressant efficacy.

If You Are Already Taking Both

Many patients start ashwagandha on their own before asking their prescriber. If that describes you, do not panic. The combination is not classified as dangerous.

Take these steps: tell your prescriber at your next visit (or sooner via patient portal). Request a lipid panel, TSH, free T4, and hepatic function panel if you have not had one in the past 8 weeks. Continue both until advised otherwise. Document the ashwagandha brand, extract type (KSM-66, Sensoril, or generic), and daily dose for your medical record.

The American Association of Clinical Endocrinology (AACE) 2023 lipid guidelines recommend that "all supplements with potential lipid or thyroid effects be documented as active medications to avoid misattribution of lab changes" [8].

Monitoring Schedule After Adding Ashwagandha to Ezetimibe

A practical timeline for lab surveillance:

| Timepoint | Labs to Check | Purpose | |-----------|--------------|---------| | Baseline (before starting ashwagandha) | Lipid panel, TSH, free T4, ALT, AST | Establish pre-supplement values | | 6 to 8 weeks | Lipid panel, TSH, free T4, ALT, AST | Detect early thyroid or hepatic shifts | | 6 months | Lipid panel, TSH | Confirm stable trajectory | | Annually | Standard lipid and metabolic panel | Ongoing surveillance |

This schedule adds two blood draws beyond what most ezetimibe patients already receive. The cost is minimal relative to the clinical clarity gained.